•  
  •  
 

Corresponding Author

Ahmed Ezzat Moawad Mohamed

Document Type

Original Article

Abstract

Background: Infection with the human papillomavirus (HPV) causes warts, sometimes called verrucae, which are benign growths on the skin and mucous membranes. Feelings of shame and rage often accompany it, and it can have a major influence on patients' quality of life.

Aim and objectives: Efficacy of intralesional 5-FU vs intralesional interferon alpha in treating warts in two separate groups of patients.

Patients and methods: The sixty patients who were chosen for this cohort had wart diagnoses and were seen in the outpatient clinics of Al-Azhar University Hospitals in Cairo's Dermatology, Venereology, and Andrology Department. The study's recruitment phase began in April 2022 and ended in April 2023.

Results: With respect to the ultimate answer, group A and group B differed significantly (P=0.005) from one another. Only seven patients (23.3%) in group A (5-fluorouracil) had a partial response, while twenty-three patients (76.7%) attained complete clearance. This group did not exhibit any signs of resistance. On the other hand, out of 30 patients in group B (Interferon alpha), 36.7% achieved full clearance, 53.3% showed partial response, and 10.0% showed resistance.

Conclusion: Palmar, planter, and common warts can be effectively treated with intralesional 5-fluorouracil (5-FU), which is also readily available, inexpensive, and of good quality. For intralesional interferon alpha to be more effective, it may be necessary to increase the number of sessions, decrease the intervals between them, or change the dosage. It is possible that people with resistant warts will benefit more from a combination of the two therapies.

Keywords

Intralesional 5-Fluorouracil; Intralesional Interferon Alpha; Warts

Subject Area

Dermatology

Download

Share

COinS